Literature DB >> 30652570

Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic.

Katherine Fleshner1, Amy Tin1, Nicole Benfante1, Sigrid Carlsson1, Andrew J Vickers1.   

Abstract

PURPOSE: To determine whether patient-reported collection of comorbidities online is sufficiently accurate to warrant use as part of a physician-reviewed, baseline medical history.
METHODS: Comorbidities were collected for a sample of 213 new prostate cancer visits to our urology clinic through an online survey (called Baseline Medical History) before the clinical encounter. The frequency distributions of comorbidities as reported by patients before physician review were compared with those documented by physicians for a sample of 298 consecutive patients presenting to the same urology clinic before the survey went live.
RESULTS: The overall frequency distribution of comorbidities and life expectancy estimates were similar between the two groups. A few comorbidity categories were reported with higher frequency in the patient-reported group compared with the physician-documented group, including neurologic comorbidities (7.5% v 1.7%; difference 6%; 95% CI, 2.0% to 10%; P = .001) and back pain (24% v 13%; difference 12%; 95% CI, 4.8% to 19%; P = .001). A similar trend was seen for vascular conditions, although the difference did not meet conventional levels of statistical significance. Genitourinary comorbidities, including problems with urination and erectile dysfunction, were better captured by the physician-reported group compared with the patient-reported group (68% v 53%; difference 15%; 95% CI, 7% to 24%; P = .001), as were other musculoskeletal comorbidities (8.7% v 1.9%; difference 7%; 95% CI, 3.2% to 11%; P = .001).
CONCLUSION: Patients completing a medical history, at their own pace and in the comfort of their own home, provide relatively accurate and complete information, even before physician review. Patient reporting of comorbidities thus seems to be a reliable starting point for the documentation of the medical history in the clinic.

Entities:  

Mesh:

Year:  2018        PMID: 30652570      PMCID: PMC6503836          DOI: 10.1200/CCI.17.00154

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  9 in total

1.  Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.

Authors:  Hyunsoon Cho; Angela B Mariotto; Bhupinder S Mann; Carrie N Klabunde; Eric J Feuer
Journal:  Am J Epidemiol       Date:  2013-07-03       Impact factor: 4.897

Review 2.  Predicting life expectancy in prostate cancer patients.

Authors:  Claudio Jeldres; Jean-Baptiste Latouff; Fred Saad
Journal:  Curr Opin Support Palliat Care       Date:  2009-09       Impact factor: 2.302

3.  Impact of comorbidity on survival among men with localized prostate cancer.

Authors:  Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Grace L Lu-Yao
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

4.  Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities.

Authors:  Ethan Basch; David Artz; Alexia Iasonos; John Speakman; Kevin Shannon; Kai Lin; Charmaine Pun; Henry Yong; Paul Fearn; Allison Barz; Howard I Scher; Mary McCabe; Deborah Schrag
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

5.  Development of a clinical prediction model to calculate patient life expectancy: the measure of actuarial life expectancy (MALE).

Authors:  M G Clarke; K P Kennedy; R P MacDonagh
Journal:  Med Decis Making       Date:  2008-12-01       Impact factor: 2.583

6.  The surgical learning curve for prostate cancer control after radical prostatectomy.

Authors:  Andrew J Vickers; Fernando J Bianco; Angel M Serio; James A Eastham; Deborah Schrag; Eric A Klein; Alwyn M Reuther; Michael W Kattan; J Edson Pontes; Peter T Scardino
Journal:  J Natl Cancer Inst       Date:  2007-07-24       Impact factor: 13.506

7.  Comparison of Patient Report and Medical Records of Comorbidities: Results From a Population-Based Cohort of Patients With Prostate Cancer.

Authors:  Fan Ye; Dominic H Moon; William R Carpenter; Bryce B Reeve; Deborah S Usinger; Rebecca L Green; Kiayni Spearman; Nathan C Sheets; Kevin A Pearlstein; Angela R Lucero; Mark R Waddle; Paul A Godley; Ronald C Chen
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

8.  Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire.

Authors:  Erica H Lee; Rajiv I Nijhawan; Kishwer S Nehal; Stephen W Dusza; Amanda Levine; Amanda Hill; Christopher A Barker
Journal:  J Skin Cancer       Date:  2015-06-09

9.  Successful external validation of a model to predict other cause mortality in localized prostate cancer.

Authors:  Matthew Kent; David F Penson; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Janet L Stanford; Antoinette M Stroup; Behfar Ehdaie; Peter T Scardino; Andrew J Vickers
Journal:  BMC Med       Date:  2016-02-09       Impact factor: 8.775

  9 in total
  3 in total

1.  Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.

Authors:  Patricia Mae G Santos; Andrew R Barsky; Wei-Ting Hwang; Curtiland Deville; Xingmei Wang; Stefan Both; Justin E Bekelman; John P Christodouleas; Neha Vapiwala
Journal:  Cancer       Date:  2019-09-10       Impact factor: 6.860

2.  Comorbidity Prevalence and Impact on Quality of Life in Gay and Bisexual Men Following Prostate Cancer Treatment.

Authors:  Ryan Haggart; Elizabeth Polter; Michael Ross; Nidhi Kohli; Badrinath R Konety; Darryl Mitteldorf; William West; B R Simon Rosser
Journal:  Sex Med       Date:  2021-10-08       Impact factor: 2.491

Review 3.  Treating the patient and not just the cancer: therapeutic burden in prostate cancer.

Authors:  Daniel E Spratt; Neal Shore; Oliver Sartor; Dana Rathkopf; Kara Olivier
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-18       Impact factor: 5.554

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.